MX2015006249A - Ester nitrico de saquinavir para inmunomodulacion. - Google Patents
Ester nitrico de saquinavir para inmunomodulacion.Info
- Publication number
- MX2015006249A MX2015006249A MX2015006249A MX2015006249A MX2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- syndrome
- saquinavir
- disease
- autoimmune
- Prior art date
Links
- 229960005550 OX1001 Drugs 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- SPHXNRBWPVEVAS-UGJKXSETSA-N ox1001 Chemical compound C([C@@H]([C@H](O[N+]([O-])=O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 SPHXNRBWPVEVAS-UGJKXSETSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000026872 Addison Disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 abstract 1
- 206010004053 Bacterial toxaemia Diseases 0.000 abstract 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 206010004659 Biliary cirrhosis Diseases 0.000 abstract 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010018634 Gouty Arthritis Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 208000013222 Toxemia Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- 208000010157 sclerosing cholangitis Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728330P | 2012-11-20 | 2012-11-20 | |
| PCT/EP2013/074264 WO2014079868A1 (en) | 2012-11-20 | 2013-11-20 | Saquinavir-no for immunomodulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015006249A true MX2015006249A (es) | 2015-12-03 |
Family
ID=49759262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006249A MX2015006249A (es) | 2012-11-20 | 2013-11-20 | Ester nitrico de saquinavir para inmunomodulacion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150283127A1 (enExample) |
| EP (1) | EP2922545B1 (enExample) |
| JP (1) | JP6283680B2 (enExample) |
| KR (1) | KR20150084862A (enExample) |
| CN (1) | CN104822379B (enExample) |
| AU (1) | AU2013349804A1 (enExample) |
| BR (1) | BR112015011299A2 (enExample) |
| CA (1) | CA2891771A1 (enExample) |
| IL (1) | IL238866A0 (enExample) |
| MX (1) | MX2015006249A (enExample) |
| WO (1) | WO2014079868A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127858A (zh) * | 2014-07-26 | 2014-11-05 | 滨州医学院 | 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200003674T2 (tr) * | 1998-06-09 | 2001-07-23 | J. Embro William | Epidermal iltihapların ve enfeksiyonların tedavisine yönelik metot. |
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| US20030138423A1 (en) * | 2001-12-14 | 2003-07-24 | Cedars-Sinai Medical Center | Method of treating inflammation with HIV-1 protease inhibitors and their derivatives |
| HRP20140929T1 (hr) * | 2008-08-01 | 2014-12-05 | Onconox Aps | Antitumorska svojstva no-modificiranih inhibitora proteaze |
| WO2012088305A1 (en) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
-
2013
- 2013-11-20 BR BR112015011299A patent/BR112015011299A2/pt not_active IP Right Cessation
- 2013-11-20 AU AU2013349804A patent/AU2013349804A1/en not_active Abandoned
- 2013-11-20 MX MX2015006249A patent/MX2015006249A/es unknown
- 2013-11-20 WO PCT/EP2013/074264 patent/WO2014079868A1/en not_active Ceased
- 2013-11-20 EP EP13802901.2A patent/EP2922545B1/en not_active Not-in-force
- 2013-11-20 JP JP2015542309A patent/JP6283680B2/ja not_active Expired - Fee Related
- 2013-11-20 CN CN201380060071.4A patent/CN104822379B/zh not_active Expired - Fee Related
- 2013-11-20 CA CA2891771A patent/CA2891771A1/en not_active Abandoned
- 2013-11-20 US US14/443,402 patent/US20150283127A1/en not_active Abandoned
- 2013-11-20 KR KR1020157013049A patent/KR20150084862A/ko not_active Withdrawn
-
2015
- 2015-05-18 IL IL238866A patent/IL238866A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015537023A (ja) | 2015-12-24 |
| WO2014079868A1 (en) | 2014-05-30 |
| IL238866A0 (en) | 2015-06-30 |
| CN104822379A (zh) | 2015-08-05 |
| JP6283680B2 (ja) | 2018-02-21 |
| US20150283127A1 (en) | 2015-10-08 |
| EP2922545B1 (en) | 2016-09-21 |
| CN104822379B (zh) | 2017-08-25 |
| HK1212895A1 (zh) | 2016-06-24 |
| KR20150084862A (ko) | 2015-07-22 |
| EP2922545A1 (en) | 2015-09-30 |
| CA2891771A1 (en) | 2014-05-30 |
| AU2013349804A1 (en) | 2015-06-04 |
| BR112015011299A2 (pt) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003008A (es) | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos. | |
| SI3230298T1 (sl) | Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom | |
| IN2014MN02658A (enExample) | ||
| IN2014MN02657A (enExample) | ||
| IN2014MN02652A (enExample) | ||
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| MX351368B (es) | Compuestos heteroarilo y metodos para utilizarlos. | |
| WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
| MY183974A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| MY162397A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| JP2018501215A5 (enExample) | ||
| PH12016501864A1 (en) | Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| ZA201107446B (en) | Compounds for the treatment of metabolic disorders | |
| CL2015002606A1 (es) | Compuesto. | |
| GB0904285D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| NZ620074A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| HUE056265T2 (hu) | Igmezin Alzheimer-kór kezelésében történõ alkalmazásra | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| BR112015011299A2 (pt) | saquinavir-no para imunomodulação | |
| WO2016059269A8 (es) | Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas | |
| WO2012080243A3 (en) | Process for the preparation of atovaquone | |
| IL254766A0 (en) | A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome | |
| NZ728660A (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor |